Clinical Trial

MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of the study is to construct a noninvasive approach using 68Ga-labeled bicyclic peptide radiotracer to detect the matrix metalloproteinase 14 (MMP14, MT1-MMP) expression of tumor lesions in patients with solid tumors and to identify patients benefiting from MMP14 targeting treatment.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-12
Trial Details
NCT Number NCT06719856
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Solid Tumor
Enrollment 30 participants
Start Date 2025-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11